Anti-Cancer

Capmatinib (RAHIKA) 30 Tablet

$1,450.00

Capmatinib Rahika 150/200 MG Tablet is an innovative medication utilized in the treatment of metastatic non-small cell lung cancer (NSCLC) with specific genetic mutations. It contains capmatinib as its active ingredient, a potent and selective inhibitor of the mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase, which is frequently dysregulated in certain types of NSCLC.

Strength	Choose an option150mg200mg
	Clear

Quantity

Capmatinib (RAHIKA) 30 Tablet quantity

Add to cart

Sku:

N/A

Tag:

Capmatinib RAHIKA

Description

Capmatinib Rahika 150/200 MG Tablet is an innovative medication utilized in the treatment of metastatic non-small cell lung cancer (NSCLC) with specific genetic mutations. It contains capmatinib as its active ingredient, a potent and selective inhibitor of the mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase, which is frequently dysregulated in certain types of NSCLC.

Key Features:

• MET Inhibitor: Capmatinib exerts its therapeutic effects by selectively inhibiting the activity of the MET receptor tyrosine kinase, which plays a crucial role in tumor growth, metastasis, and resistance to therapy in NSCLC with MET exon 14 skipping mutations. By targeting MET signaling pathways, capmatinib effectively suppresses tumor progression and improves patient outcomes.
• Treatment of NSCLC: Capmatinib Rahika 150/200 MG Tablet is indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping mutations, as detected by an FDA-approved test. It offers a targeted treatment option for patients with this specific genetic alteration, who may not respond to standard therapies.
• Oral Administration: Capmatinib Rahika 150/200 MG Tablet is administered orally, typically once or twice daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical trials have demonstrated the efficacy of capmatinib in producing durable responses and prolonging progression-free survival in patients with metastatic NSCLC harboring MET exon 14 skipping mutations. It has shown superiority over standard chemotherapy regimens, offering new hope for patients with this molecular subtype of NSCLC.
• Safety Profile: Capmatinib has a manageable safety profile, with common side effects including peripheral edema, nausea, fatigue, vomiting, and dyspnea. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
• Patient Education: Patients prescribed Capmatinib Rahika 150/200 MG Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Capmatinib Rahika 150/200 MG Tablet should be initiated and monitored by a qualified oncologist or healthcare provider experienced in the management of NSCLC. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Capmatinib Rahika 150/200 MG Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to targeted therapy medications is crucial to improving patient outcomes and quality of life for those with specific genetic mutations driving cancer progression.

Additional information